Mucobene

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Mucobene

Quick Facts

Property Description
Active Ingredient Acetylcysteine (N-acetyl-L-cysteine)
Form Effervescent tablets, Soluble powder/granules, Solutions
Pharmacological Class Mucoactive agent, Mucolytic agent
General Purpose To thin thick mucus and facilitate airway clearance
Origin Synthetic derivative (Thiol derivative of L-cysteine)

What is Mucobene and Its Chemical Identity?

Mucobene is a pharmaceutical preparation defined by its sole active component, Acetylcysteine, which functions as a single-component product. Acetylcysteine is classified chemically as a thiol derivative, meaning it is a synthetic derivative based on the structure of the naturally occurring amino acid, L-cysteine. This specific chemical structure is the entire basis of the drug's effect. Mucobene is frequently marketed as an effervescent tablet formulation, a characteristic presentation that facilitates quick dissolution for oral administration, and is intended for use across different patient groups, including both adults and children.

Mucobene’s Pharmacological Classification and General Purpose

Mucobene is categorized as a mucoactive agent and is specifically a mucolytic agent. The fundamental general purpose of a mucolytic is to address respiratory conditions characterized by the presence of abnormally thick and viscid mucous secretions that obstruct the airways. Acetylcysteine functions by chemically targeting and breaking the strong protein bonds (disulfide bonds) within the mucus, thereby promoting its essential liquefaction. This therapeutic action is clinically recognized for supporting patients who struggle to clear thick phlegm from their chest, facilitating relief from congestion.

Available Forms of Mucobene

The active ingredient is recognized as crucial for both its mucolytic properties and its unique use as a specific antidote. For instance, Acetylcysteine is approved for acute clinical use through the intravenous route. The dosage forms of Mucobene intended for respiratory use include effervescent tablets and soluble powder/granules for oral intake, as well as solutions intended for inhalation, confirming the drug's versatile delivery methods.

What side effects are possible with Mucobene?

Possible Side Effects and Safety Information

Official regulatory documentation classifies the possible side effects of Acetylcysteine (Mucobene) across several System-Organ Classes, primarily involving the Gastrointestinal, Dermatological, and Immune Systems. Frequency classifications guide the understanding of how often these reactions may appear.

Adverse Reaction Frequency (Regulatory Classification)

Classification Documented Reactions (Examples)
Common Nausea, Vomiting, Rash, Pruritus (itching), Urticaria/facial flushing.
Uncommon Headache, Tinnitus (ringing in the ears), Fever, general Hypersensitivity.
Very Rare Anaphylactic shock, Anaphylactoid reaction.
Not Known Stevens-Johnson syndrome, Toxic epidermal necrolysis.

Serious adverse reactions are specifically documented in regulatory labels. These include Anaphylactic Shock and other severe hypersensitivity reactions, as well as reports of severe cutaneous adverse reactions (SCARs), such as Stevens-Johnson syndrome and Toxic Epidermal Necrolysis. The potential for Bronchospasm is also noted, and this may necessitate immediate cessation of use.

Safety Considerations for Specific Conditions

Official labeling includes specific notes for certain patient populations and pre-existing conditions. Patients with Bronchial Asthma require close monitoring during administration due to the increased, documented risk of bronchospasm. Caution is also specified for individuals with conditions that predispose them to bleeding, such as peptic ulcers or esophageal varices, due to a noted risk of upper gastrointestinal hemorrhage. Furthermore, administration is contraindicated in patients with known hypersensitivity to the active substance or its excipients.

Overdose and Emergency Response

The official regulatory documentation for Acetylcysteine (Mucobene) defines its overdose profile through documented clinical manifestations and required emergency actions. Overdose may present with common gastrointestinal disturbances such as nausea, vomiting, and diarrhea. More severe systemic signs include flushing, rash, and hypotension (low blood pressure), sometimes leading to tachycardia or bronchospasm.

A key regulatory warning focuses on the potential for severe anaphylactoid reactions and respiratory distress, which require immediate medical attention. If severe signs are observed, the administration of the medicine must be immediately discontinued. The management framework, defined in official labeling, is entirely symptomatic and supportive, as no specific antidote is known for an Acetylcysteine overdose.

Due to the risk of complications, patients require careful observation and monitoring of fluid balance and electrolyte status. Specific regulatory caution is placed on children and patients weighing less than 40 kg, where excessive fluid administration can lead to fluid overload, potentially causing hyponatraemia and seizures.

Therapeutic Uses of Mucobene

What Mucobene treats: main uses and benefits

Mucobene is applicable within clinical settings that involve acute or unstable symptom patterns related to the respiratory system. It is relevant for easing symptoms related to physical discomfort and contributes to easing the overall symptom load associated with chest congestion. This type of medication is commonly used to help with symptom clusters that create noticeable functional strain in conditions such as chronic bronchitis, bronchiectasis, and other respiratory disorders where cough is productive.

This approach is considered relevant when supportive symptom management is appropriate for a variety of respiratory tract problems. It is applied when conditions produce significant symptomatic burden, particularly in scenarios involving recurrent or episodic manifestations. By providing support that helps ease the overall symptom burden, this medicine may assist with maintaining functional stability in individuals who experience heightened discomfort or tension.

The patient-oriented support contributes to providing relief when symptoms interfere with routine activities.


Quick Fact: May provide support for symptoms related to Thick Mucus

Eligibility and Restrictions for Use

Who can and cannot use Mucobene?

The official eligibility for Mucobene is strictly defined by regulatory criteria detailing who is permitted, restricted, or prohibited from using the medicine.

Absolute Contraindications

The medicine is formally contraindicated for individuals with a known hypersensitivity to Acetylcysteine or to any of the product's excipients. Mucolytic use is also prohibited in children under two years of age due to the physiological constraint of an underdeveloped ability to efficiently clear mucus. Additionally, certain oral formulations are contraindicated in patients with specific hereditary metabolic disorders, such as fructose intolerance.

Conditional and Restricted Use

Regulatory documents establish that use requires caution in several populations. Patients with a history of peptic ulcer disease or existing bronchial asthma must be closely monitored, and the medicine must be discontinued immediately if bronchospasm develops. For pregnant and nursing individuals, administration should occur only after a strict assessment of the clinical risk-benefit ratio due to limited human data. Eligibility is established for adults and conditionally for children two years and older and adolescents, depending on the specific product formulation.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section details the officially documented interaction patterns for Acetylcysteine (Mucobene) as noted in government regulatory labeling. The interactions are classified based on effects on the body (pharmacodynamic) and changes to drug exposure (pharmacokinetic or chemical).

Pharmacodynamic and Chemical Restrictions

  • Nitroglycerin (NTG): Concurrent administration is documented to potentiate the vasodilator effects of NTG, carrying a formal risk of causing significant hypotension that requires careful monitoring.
  • Antitussive Drugs: Co-administration with cough suppressants is formally discouraged by regulatory authorities. The combination can prevent the clearance of thinned mucus, potentially leading to a build-up of bronchial secretions.
  • In-Vitro Incompatibility: It is explicitly advised not to mix Mucobene powder or solution directly with other medicinal products in the same solution due to documented potential chemical inactivation.

Pharmacokinetic and Efficacy Alterations

The official drug labeling outlines specific interactions that alter drug exposure or efficacy:

  • Oral Antibiotics: A mandatory timing separation rule is in effect. Oral antibiotics must be administered at least two hours before or after Mucobene to prevent the risk of antibiotic inactivation shown in testing. This rule applies generally to ensure full efficacy.
  • Carbamazepine: Concomitant use is documented to reduce the exposure of Carbamazepine, which may result in sub-therapeutic levels of that medicine.
  • Activated Charcoal: This substance may reduce the overall efficacy of Acetylcysteine through physical adsorption in the digestive system, thereby decreasing its absorption.

Mechanism of Action

The mechanism of Acetylcysteine involves two distinct pathways that alter the physical and biochemical characteristics of secretions.

Direct Chemical Liquefaction (Mucolytic Action)

This domain focuses on the chemical disruption of the physical structure of respiratory secretions. The core mechanism is the ability of the molecule's free sulfhydryl ( -SH) group to act as a reducing agent, directly targeting and breaking the strong disulfide bonds ( S-S) that heavily cross-link the large mucin glycoproteins . This reaction results in the depolymerization of the mucin matrix, which reduces the viscosity and elasticity of the mucus. The resulting physiological effect is the physical thinning of the airway secretions, which supports mucociliary transport out of the lungs.

Support for Cellular Redox and Antioxidant Reserves

This mechanism involves the drug's role in the body's intracellular defense systems. Acetylcysteine functions as a vital precursor to L-cysteine, the rate-limiting substrate required for the synthesis of Glutathione (GSH), the cell’s primary endogenous antioxidant. By supporting the replenishment of the GSH pool, the drug contributes to the cellular redox status in the pulmonary epithelium. This action is linked to the functional integrity of the respiratory lining and modulates downstream inflammatory signaling pathways sensitive to oxidative stress.

Dosage and Administration Information

Administration Guidelines for Mucobene (Acetylcysteine)

This section outlines the usage instructions for Mucobene. These instructions pertain to the preparation, dosing, and administration of the medication.


Category Statement
Route of Administration Oral use, specifically as a solution after proper preparation.
Dosing Schedule Standard dose for adults and adolescents over 12 years is typically 200 mg per single dose, administered three times a day. The maximum recommended daily dose is 600 mg.
Timing in Relation to Meals Not explicitly bound to meal times, but for certain uses, adequate fluid intake is recommended to support the intended effect.
Preparation Requirements Effervescent tablets or powder for oral solution must be fully dissolved in a glass of water just before consumption. The solution should be taken shortly after preparation.
Age-Group Rules Administration to children younger than two years is not recommended.
Special Procedural Conditions The intake of certain antibiotics (e.g., tetracyclines, cephalosporins) must be separated from Mucobene intake by at least two hours to avoid potential interaction outside the body. Abundant overall fluid intake is encouraged during the course of administration.

Resulting Procedural Structure

The established use protocol requires the dose to be prepared by dissolving the tablet or powder in water immediately before ingestion, ensuring it is taken by the oral route. The product is administered on a multiple-times-daily frequency to meet the 600 mg daily limit for adults. The protocol requires that the patient observe a two-hour interval when taking specified antibiotics concurrently, framing the proper use within clear contextual constraints based on the active ingredient.

Recent Clinical Evidence

Research evidence / Overview of studies for Mucobene

This section will summarize the research base, primarily derived from large-scale randomized controlled trials and meta-analyses, focusing on outcomes related to respiratory health status and the monitoring of symptom frequency over long periods.


Evidence for use in Chronic Bronchitis and COPD

Studies have been conducted using Randomized Controlled Trials (RCTs) against a placebo to explore the long-term patterns associated with Mucobene use in adults and older adults. The main outcomes research examined were the frequency of acute exacerbations (or symptom flare-ups) over time, and whether there were changes in patient-reported outcomes describing perceived discomfort and overall health-related Quality of Life (QoL).

Across the aggregate evidence from multiple clinical trials, studies reported patterns related to the frequency of acute exacerbations that sometimes varied when compared to placebo in the observed populations. Findings were mixed regarding whether the treatment was associated with measurable changes in lung function measures over time.

What remains uncertain is the consistency of the findings across all major trials, as some have shown differing results. Furthermore, the long-term effects are not fully established regarding whether the medicine was observed in studies to be associated with sustained changes in the long-term decline of lung function.

Evidence for use during Acute Symptom Flare-ups

Research has explored the use of Mucobene during short-term symptom flare-ups by conducting short-term RCTs with hospitalized adult patients experiencing an Acute Exacerbation of COPD (AECOPD). These studies evaluated outcomes related to the rate of clinical symptom improvement and the duration of the hospital stay.

The studies reported that outcomes were short-term and limited to the duration of the acute episode. When the agent was studied as an addition to standard hospital care, findings were mixed. Data show patterns related to little or no measurable difference between the agent and the control group in outcomes like the length of hospital stay or the rate of symptom resolution.

Key Studies & References

  1. ACETYLCYSTEINE inhalant - DailyMed (FDA-referenced label for mucolytic use)

Frequently Asked Questions (FAQ)

Common questions about Mucobene (FAQ)

Q: Does Mucobene manage symptoms or target the underlying cause of the condition?

According to official product information, Mucobene (Acetylcysteine) is classified as a mucoactive and mucolytic agent. Its fundamental purpose is to chemically thin thick mucus and facilitate clearance from the airways. This action is considered a method of managing respiratory symptoms rather than addressing the primary underlying cause of the condition.

Q: Is there a list of signs or symptoms that require immediate medical attention while taking Mucobene?

Official regulatory labels describe the potential for serious reactions, including anaphylactic shock and severe skin reactions like Stevens-Johnson syndrome. Signs that typically indicate that medical attention may be required are related to the sudden onset of severe allergic reactions, such as difficulty breathing, swelling, chest tightness, or the appearance of a severe, widespread rash.

Q: What are the known long-term effects of taking Mucobene for an extended period?

Studies have examined the long-term use of Mucobene in chronic conditions. However, research summaries indicate that the consistency of sustained findings remains uncertain across all major trials, particularly concerning long-term changes in lung function decline.

Q: Are there any specific foods, drinks, or supplements that should be avoided with Mucobene?

Official documents note that the supplement Activated Charcoal may reduce the medicine's efficacy if taken concurrently. Furthermore, concurrent intake of certain oral antibiotics requires a minimum two-hour separation due to the risk of inactivation. Adequate fluid intake is generally recommended during the course of administration, as stated in regulatory documents.

Q: Is a patient with a known allergy to other similar drugs restricted from using Mucobene?

Regulatory guidelines state that Mucobene is formally contraindicated for individuals with a known hypersensitivity to the active ingredient Acetylcysteine or the product's inactive ingredients (excipients). Official documentation does not typically mandate restriction solely based on a known allergy to other drugs that are only chemically similar.

Q: Can Mucobene be safely split, chewed, or crushed?

Official administration instructions require that the effervescent tablets or powder be fully dissolved in a glass of water immediately before consumption to prepare the oral solution. The preparation method, which requires full dissolution, indicates that the solid form is not intended to be chewed or swallowed whole.

Q: Can Mucobene cause mood changes or affect mental focus?

The list of adverse reactions includes drowsiness as a possible side effect. While drowsiness may affect attention or focus, official regulatory documents do not typically list specific mood changes as a documented effect.

Q: Does Mucobene affect the ability to drive or operate machinery?

Official side effect listings note the possibility of drowsiness, which may affect a patient's attention and reaction time. Since drowsiness is listed, patients should be aware that their reaction time and attention may be affected when operating machinery or driving.

Q: Does Mucobene interact with common over-the-counter pain relievers?

Official interaction warnings do not cite an issue between Mucobene and Acetaminophen (a common OTC pain reliever) in the mucolytic setting. Regulatory documents also specify that the active ingredient, Acetylcysteine, is primarily cited as the specific antidote used for treating Acetaminophen overdose.

Q: Does Mucobene interact with birth control pills?

Standard drug interaction databases, which inform regulatory guidance, often indicate that no specific interaction has been found or formally cited between Acetylcysteine and hormonal birth control products.

Q: What is the general procedure if a dose of Mucobene is missed?

Regulatory consumer information generally describes the recommended procedure for a missed dose. This guidance indicates taking the dose as soon as it is remembered, unless it is close to the next scheduled time, in which case the missed dose is skipped. The guidance specifies that the dose is not to be doubled to compensate for the skipped one.

Q: Is Mucobene available as a generic formulation?

The active ingredient, Acetylcysteine, is an established chemical entity. Official regulatory records confirm that generic versions containing Acetylcysteine are widely available from various manufacturers.

Q: Why do some people online say Mucobene made them feel tired?

Official regulatory documents list drowsiness as an adverse effect of Mucobene. Drowsiness is a documented side effect that may be reported by patients as a feeling of fatigue or tiredness.

Q: Why does my Mucobene tablet look different from the one pictured online?

Since the active ingredient, Acetylcysteine, is produced by different companies, the appearance of the tablets can vary. Tablets often change in shape, color, or marking due to the use of different inactive ingredients (excipients) and manufacturing processes.

Q: Is Mucobene a controlled substance?

Based on government scheduling databases, Acetylcysteine is an established drug that is not classified as a controlled substance by major regulatory bodies.

How should Mucobene be stored and disposed of?

How to Store and Dispose of Mucobene

Mucobene must be stored according to regulatory requirements to ensure its stability. The product should be kept at Controlled Room Temperature, specifically between 20 C to 25 C (68 F to 77 F), with permitted temperature excursions up to 30 C.

Storage Conditions

  • Protection: The medicine must be stored in its original container, kept tightly closed to protect it from moisture, and shielded from light.
  • Child Safety: All forms of the product must be kept out of the sight and reach of children.
  • Prepared Solution Stability: If the powder or tablet is reconstituted into a solution, it must be used immediately. Any unused portion of a prepared solution must be discarded.

Disposal Instructions

Expired or unused Mucobene must not be disposed of in household trash or wastewater. Disposal must strictly adhere to the local pharmaceutical waste requirements mandated by government regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Mucobene found in:

A-Z Index: